Clinical Trial Details
| Trial ID: | L7294 |
| Source ID: | NCT00924053 |
| Associated Drug: | Egt0001474 |
| Title: | Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT00924053/results |
| Conditions: | Diabetes Mellitus Type 2 |
| Interventions: | DRUG: EGT0001474|DRUG: Placebo |
| Outcome Measures: | Primary: Safety and Tolerability of EGT0001474, Safety and tolerability were measured in terms of the number of mild, moderate and severe adverse events experienced by any participants., 25 days|AUC 0-t, Area under the plasma concentration-time curve from time 0 to time t, 3 days|AUC0-24, Area under the plasma concentration-time curve from time 0 to hour 24, 3 days|AUC Inf, Area under the plasma concentration-time curve from time 0 to infinity, 3 days|Cmax, Maximum plasma concentration, 3 days|Tmax, Time of maximum plasma concentration, 3 days|λz, Terminal phase rate constant, 3 days|t1/2, Apparent terminal half life, 3 days|CL/F, The apparent rate of oral clearance of EGT0001474.Oral clearance was defined as rate of drug removal from the body after oral administration., 3 days|Vz/F, Apparent volume of distribution, 3 days | |
| Sponsor/Collaborators: | Sponsor: Theracos |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 24 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2009-06 |
| Completion Date: | 2009-07 |
| Results First Posted: | 2011-08-17 |
| Last Update Posted: | 2019-06-17 |
| Locations: | dgd Research Inc., a Cetero Research Company, San Antonio, Texas, 78229, United States |
| URL: | https://clinicaltrials.gov/show/NCT00924053 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|